{"id":"fluticasone-propionate","rwe":[],"_fda":{"id":"49fdba31-142a-2157-e063-6294a90a01f3","set_id":"0107ad1c-1d8e-434c-a91f-dd2caf4fa5e5","openfda":{"upc":["0372888248011"],"unii":["O2GMZ0LF5W"],"route":["NASAL"],"rxcui":["1797907"],"spl_id":["49fdba31-142a-2157-e063-6294a90a01f3"],"brand_name":["Fluticasone Propionate"],"spl_set_id":["0107ad1c-1d8e-434c-a91f-dd2caf4fa5e5"],"package_ndc":["72888-248-01"],"product_ndc":["72888-248"],"generic_name":["FLUTICASONE PROPIONATE NASAL"],"product_type":["HUMAN OTC DRUG"],"substance_name":["FLUTICASONE PROPIONATE"],"manufacturer_name":["Advagen Pharma Ltd."],"application_number":["ANDA219060"],"is_original_packager":[true]},"purpose":["Purpose Allergy symptom reliever"],"version":"2","warnings":["Warnings Only for use in the nose. Do not spray into your eyes or mouth."],"questions":["Questions or comments? call toll-free 866-488-0312 Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520 Made in Italy Rev. 02, 01/2025"],"ask_doctor":["Ask a doctor before use if you have or had glaucoma or cataracts Ask a doctor or pharmacist before use if you are taking medicine for HIV infection (such as ritonavir) a steroid medicine for asthma, allergies or skin rash ketoconazole pills (medicine for fungal infection) When using this product the growth rate of some children may be slower stinging or sneezing may occur for a few seconds right after use do not share this bottle with anyone else as this may spread germs remember to tell your doctor about all the medicines you take, including this one Stop use and ask a doctor if you have, or come into contact with someone who has, chicken pox, measles or tuberculosis your symptoms do not get better within 7 days of starting use or you get new symptoms such as severe facial pain or thick nasal discharge. You may have something more than allergies, such as an infection. you get a constant whistling sound from your nose. This may be a sign of damage inside your nose. you get an allergic reaction to this product. Seek medical help right away. you get new changes to your vision that develop after starting this product you have severe or frequent nosebleeds If pregnant or breast –feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"do_not_use":["Do not use in children under 4 years of age to treat asthma if you have an injury or surgery to your nose that is not fully healed if you have ever had an allergic reaction to this product or any of the ingredients"],"effective_time":"20260204","active_ingredient":["Active Ingredient (in each spray) Fluticasone propionate (glucocorticold) 50 mcg"],"inactive_ingredient":["Inactive ingredients benzalkonium chloride, dextrose, microcrystalline cellulose, phenylethyl alcohol, polysorbate 80, purified water, sodium carboxymethylcellulose"],"indications_and_usage":["Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing"],"spl_unclassified_section":["FLUTICASONE PROPIONATE NASAL SPRAY, USP QUESTIONS & ANSWERS WHAT FLUTICASONE PROPIONATE NASAL SPRAY , USP IS, HOW TO USE IT, AND WHAT TO EXPECT UNDERSTANDING FLUTICASONE PROPIONATE NASAL SPRAY, USP What Fluticasone Propionate Nasal Spray, USP is, and how it works. What is Fluticasone Propionate Nasal Spray, USP? Fluticasone Propionate Nasal Spray, USP is an effective allergy medicine that you can buy without a prescription. It works directly in the nose to help block your allergic reactions. Fluticasone Propionate Nasal Spray, USP relieves allergy symptoms caused by pollen, mold, dust and pets. What is the active ingredient in Fluticasone Propionate Nasal Spray, USP? The active ingredient in Fluticasone Propionate Nasal Spray, USP is called fluticasone propionate. Fluticasone propionate is a glucocorticoid – a substance produced naturally by your body to help fight inflammation. It works in your nose to relieve your allergy symptoms. Barely any of it travels through your body. It’s been prescribed by doctors for over 20 years, and used effectively by millions. A glucocorticoid is a kind of steroid that is different from the anabolic (muscle-building) steroids sometimes misused by athletes. In fact, world class athletes are allowed to use glucocorticoids during competition to treat their allergies. Who should not use Fluticasone Propionate Nasal Spray, USP? For complete guidance, check the Drug Facts label on the back of the Fluticasone Propionate Nasal Spray, USP package. Can I use Fluticasone Propionate Nasal Spray, USP for asthma? No, Fluticasone Propionate Nasal Spray, USP is not a treatment for asthma. Ask your doctor what medicine to take for your asthma. Can I use Fluticasone Propionate Nasal Spray, USP for colds? No, use Fluticasone Propionate Nasal Spray, USP to treat only your allergies – not your cold symptoms. If you’re not sure whether your symptoms come from allergies or a cold, ask your doctor. What happens when you have allergies? Allergies start when allergens like pollen or pet dander enter your body and trigger your immune system to respond. Your body’s natural response is to release multiple inflammatory substances, (also referred to as mediators) that cause your allergy symptoms. How does Fluticasone Propionate Nasal Spray, USP work? Fluticasone Propionate Nasal Spray, USP works right in your nose to help block your allergic reaction at the source to relieve the symptoms that make you uncomfortable. Fluticasone Propionate Nasal Spray, USP acts on multiple inflammatory substances, including histamine, prostaglandins, cytokines, tryptases, chemokines and leukotrienes. Most common OTC allergy pills act on histamine alone. Because of the way it works, it may take several days for Fluticasone Propionate Nasal Spray, USP to reach maximum effect. That’s why it’s best to use Fluticasone Propionate Nasal Spray, USP regularly, once a day. Fluticasone Propionate Nasal Spray, USP not only relieves sneezing, itchy nose, runny nose and itchy, watery eyes, but also relieves nasal congestion. What problems can Fluticasone Propionate Nasal Spray, USP help with? Allergies can cause uncomfortable symptoms like congestion and itchy eyes. These symptoms can be triggered by allergens like pollen, mold, dust or pet dander. Fluticasone Propionate Nasal Spray, USP helps relieve a broad range of symptoms from many allergens. For example, Fluticasone Propionate Nasal Spray, USP helps with: Who should not use Fluticasone Propionate Nasal Spray, USP or check with a doctor first? Some people should not use Fluticasone Propionate Nasal Spray, USP or need to check with a health professional first. This table offers a quick summary of these situations. If you… Here’s what to do… Are younger than 4 Do not use Fluticasone Propionate Nasal Spray, USP Are pregnant or breast-feeding Talk to a health professional before using Fluticasone Propionate Nasal Spray, USP Have or had glaucoma or cataracts Talk to your doctor before using Fluticasone Propionate Nasal Spray, USP Have an injury or surgery to your nose that is not fully healed Do not use Fluticasone Propionate Nasal Spray, USP Have ever had an allergic reaction to Fluticasone Propionate Nasal Spray, USP or any of its ingredients Do not use Fluticasone Propionate Nasal Spray, USP Are taking a medicine for HIV infection (such as ritonavir) Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP Are taking ketoconazole pills (medicine for fungal infection) Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP Are using a steroid medicine for asthma, allergies, skin rash, allergic reactions, inflammation or eye conditions Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP USING FLUTICASONE PROPIONATE NASAL SPRAY, USP How to get the best results with Fluticasone Propionate Nasal Spray, USP. Read the Drug Facts label on the back of the package or the Quick Start Guide on the other side for simple directions on using Fluticasone Propionate Nasal Spray, USP. Watch for purple color - it shows where there is different information for children ages 4-11, compared to users age 12 or older. If you still have questions about using Fluticasone Propionate Nasal Spray, USP after reading the Quick Start Guide, read this section for answers. I know how to use a nasal spray. Why do I have to follow the directions? If you don’t use the spray bottle correctly, you might not get a full dose. Without a full dose each time, you might not get the relief you deserve. Follow the simple directions in the Quick Start Guide on other side If my symptoms go away, should I stop using Fluticasone Propionate Nasal Spray, USP? You may be tempted to stop using Fluticasone Propionate Nasal Spray, USP when you start to feel better. It’s important you keep using Fluticasone Propionate Nasal Spray, USP daily as long as you’re exposed to allergens that bother you, like pollen, mold, dust or pet dander. This way you’ll keep feeling relief. If you suffer allergy symptoms only during certain times, like when pollen levels are high, you may stop using Fluticasone Propionate Nasal Spray, USP when that time ends. If you are age 12 or older and need to use daily for longer than 6 months or age 4-11 and need to use for longer than 2 months a year, check with your doctor. What if I miss a dose by accident? If you miss a dose, just use your regular dose the next day. Don’t add an extra dose to make up for it. Can I keep using Fluticasone Propionate Nasal Spray, USP year round ? Some people suffer from allergies all year. If you are age 12 or older and have used Fluticasone Propionate Nasal Spray, USP steadily for six months or age 4-11 and have used for two months a year, check with your doctor to make sure it’s OK to keep using Fluticasone Propionate Nasal Spray, USP daily. In fact, it’s a good idea for anyone with persistent allergies to talk with a doctor every so often about symptoms and medicines. Can I share my Fluticasone Propionate Nasal Spray, USP? Do not share a bottle of Fluticasone Propionate Nasal Spray, USP. Sharing the bottle can spread germs, because you insert the nozzle in your nose. Can I spray Fluticasone Propionate Nasal Spray, USP in my eyes or mouth? No, Fluticasone Propionate Nasal Spray, USP is meant to work only in your nose to relieve your allergy symptoms, including itchy, watery eyes. Never spray Fluticasone Propionate Nasal Spray, USP in your eyes or your mouth. Some decongestants may increase blood pressure. Does Fluticasone Propionate Nasal Spray, USP increase blood pressure? When used as directed, Fluticasone Propionate Nasal Spray, USP does not increase blood pressure. Won’t I waste product by priming? It’s not a waste to prime the pump, because it helps you get a full dose. Getting a full dose is important for getting the relief you deserve. See the Quick Start Guide for when and how to prime the pump. Don’t worry about running out due to priming. There is enough medicine in the spray bottle to allow for priming sprays plus the number of sprays labeled on the bottle. Always point the spray bottle away from your face when priming. How long should a bottle of Fluticasone Propionate Nasal Spray, USP last? This table shows roughly how long your bottle will last. It assumes you follow the instructions for priming the pump, and that those age 12 or older use two sprays in each nostril every day while children age 4-11 use one spray in each nostril every day. After you’ve used the number of sprays shown on the label, each spray may not deliver a full dose — even if there is liquid left in the bottle. If the label says… The bottle should last age 12+… The bottle should last age 4-11… 120 sprays 4 weeks 8 weeks Is Fluticasone Propionate Nasal Spray, USP OK to use with other medicines? You should tell your doctor about all the medicines you take, including Fluticasone Propionate Nasal Spray, USP. Fluticasone Propionate Nasal Spray, USP can be used with most non-prescription and prescription medicines. However, there are a few medicines to look out for because they may cause the level of Fluticasone Propionate Nasal Spray, USP in your body to become too high. Just to be safe, check the table on next plane to see if you’re taking any of these medicines. If you’re taking… Here’s what to do… Medicines for HIV infection (such as ritonavir) Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP Medicines with glucocorticoids including some medicines for skin rash such as eczema, asthma, inflammation, allergic reactions or eye conditions Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP Ketoconazole Pills for fungal infection Talk to your doctor or pharmacist before using Fluticasone Propionate Nasal Spray, USP What are the differences in the way children age 4-11 should use Fluticasone Propionate Nasal Spray, USP? Children age 4-11 should use a lower dose of Fluticasone Propionate Nasal Spray, USP for a shorter period of time. Ages Children 4-11 years of age Users 12 years of age and older Dosage 1 spray in each nostril once daily Up to 2 sprays in each nostril once daily Duration before checking with a doctor Up to 2 months of use a year Up to 6 months of daily use Why is the use of Fluticasone Propionate Nasal Spray, USP for children age 4-11 limited to 2 months a year before checking with a doctor? When used long-term, intranasal glucocorticoids like Fluticasone Propionate Nasal Spray, USP may cause the growth rate of some children to be slower. Whether this will affect a child’s ultimate height is not known. As a precaution, children should use for the shortest amount of time necessary to achieve symptom relief. Talk to your child’s doctor if your child needs to use the spray for longer than 2 months a year. WHAT TO EXPECT What it’s like to use Fluticasone Propionate Nasal Spray, USP. How soon will I get relief? You may start to feel relief the first day you use Fluticasone Propionate Nasal Spray, USP. Keep using it every day, though. It takes several days before Fluticasone Propionate Nasal Spray, USP builds up to full effectiveness. How long will the relief last? Fluticasone Propionate Nasal Spray, USP is meant to control your symptoms every day, all day and all night. To help you get this lasting relief, it’s important to use Fluticasone Propionate Nasal Spray, USP regularly, once a day. Does Fluticasone Propionate Nasal Spray, USP cause a “rebound” effect? No, Fluticasone Propionate Nasal Spray, USP does not cause a rebound effect. Some nasal decongestant sprays may cause your nasal passages to swell up even more when you use them too often or for longer than their label says you should (three days). This is sometimes called a “rebound effect.” Fluticasone Propionate Nasal Spray, USP is a different kind of medicine and does not cause any rebound effect. You can use Fluticasone Propionate Nasal Spray, USP for up to six months if you are age 12 or older or up to two months a year if you are age 4-11 before checking with a doctor. Will Fluticasone Propionate Nasal Spray, USP make me drowsy? No, Fluticasone Propionate Nasal Spray, USP does not cause drowsiness. Some allergy medications can cause drowsiness, but Fluticasone Propionate Nasal Spray, USP does not. Why does Fluticasone Propionate Nasal Spray, USP have a smell? The light floral scent you may notice comes from one of the important ingredients in the Fluticasone Propionate Nasal Spray, USP formula. No fragrance is added to Fluticasone Propionate Nasal Spray, USP. What if little or nothing is spraying out? Try priming the spray bottle. It may take a few pumps to get the dispenser spraying again. If that doesn’t work, the spray nozzle may be clogged. You can clean it following the directions in the Quick Start Guide on the other side. What if I feel stinging in my nose, or I sneeze? Some people may feel a slight stinging, or may sneeze, after spraying Fluticasone Propionate Nasal Spray, USP in their nostrils. This feeling should go away in a few seconds. What if I feel or taste the medicine in my throat? Generally, you can avoid this by taking a shallower breath next time you spray Fluticasone Propionate Nasal Spray, USP into your nostrils. For example, take the kind of breath you would use to smell a flower. What if I have chicken pox, measles or tuberculosis or come into contact with someone who does? Stop using Fluticasone Propionate Nasal Spray, USP and ask your doctor. What if I’m having severe sinus pain? If you feel severe pain in your face, have thick nasal discharge, or think you may have a sinus infection, stop using Fluticasone Propionate Nasal Spray, USP and see your doctor. Your doctor may want to consider if other medicines are needed. What if my symptoms aren’t better after one week? If you have used Fluticasone Propionate Nasal Spray, USP for a week and your allergy symptoms are not getting better, stop use and ask your doctor. You may have an infection. Does Fluticasone Propionate Nasal Spray, USP have side effects? Serious side effects are rare with Fluticasone Propionate Nasal Spray, USP because Fluticasone Propionate Nasal Spray, USP works in your nose, and barely any of it travels through your body. However, like all medicines, Fluticasone Propionate Nasal Spray, USP can cause side effects in some people. Here are some side effects that have been reported when using Fluticasone Propionate Nasal Spray, USP. If you have any concerns about side effects, talk with your doctor. Side effect What could happen What to do Allergic reaction to the product Sudden swelling of face or tongue A rash Wheezing or feeling faint If you feel any of these symptoms, stop using Fluticasone Propionate Nasal Spray, USP and see a doctor right away. Nose injury Severe or frequent nosebleeds Apply pressure to your nose. Stop using Fluticasone Propionate Nasal Spray, USP and see a doctor. Constant whistling sound that does not go away This could be a sign of damage to your nose. Stop using Fluticasone Propionate Nasal Spray, USP and see a doctor right away. Eye Conditions such as cataracts or glaucoma Cloudy vision Reduced vision Have a yearly eye exam to check for these conditions. Read the Drug Facts on the back of the Fluticasone Propionate Nasal Spray, USP package for more details. Growth effects Slower growth rate in some children while using product Talk to your doctor if you are concerned or if a child age 4-11 needs to use Fluticasone Propionate Nasal Spray, USP for longer than two months a year. Other side effects Headaches or sneezing Bad taste or smell Minor nosebleeds Dry or irritated nose or throat Talk to your doctor or pharmacist if you are concerned. STILL HAVE QUESTIONS? Call 866-488-0312 Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520 Made in Italy Rev 02, 01/2025 image description image description image description image description image description","FLUTICASONE PROPIONATE NASAL SPRAY, USP QUICK START GUIDE HOW TO START GETTING ALLERGY RELIEF RIGHT NOW USE THE RIGHT DOSE Fluticasone Propionate Nasal Spray, USP works best when you use it daily. Here’s how to get started. Children age 4-11 An adult should supervise use Use one spray in each nostril Don’t use more than one spray in each nostril per day. If you miss a dose, just use your regular dose the next day. Don’t add an extra dose. Check with doctor if a child needs to use Fluticasone Propionate Nasal Spray, USP for longer than two months a year. Users age 12 or older In your first week Use two sprays in each nostril every day. Don’t use more than two sprays in each nostril per day. After your first week if your symptoms are under control, you may reduce to one spray in each nostril every day. If your symptoms get worse, go back to two sprays in each nostril. If you miss a dose, just use your regular dose the next day. Don’t add an extra dose. WARNING: Do not spray in your eyes. Only for use in your nose. KEEP IT CLEAN A clean spray nozzle helps ensure a full dose. Clean it weekly, or if it’s clogged. Don’t try to unblock nozzle with pin or sharp object — that can damage it. Remove spray nozzle by grasping at base and pulling up. Aim away from your face and gently replace spray nozzle until you hear a soft click. Rinse under running tap, and dry at room temperature. If spray nozzle is clogged , soak in warm water. Then repeat steps 2 and 3 . GET THE RELIEF YOU NEED. Fluticasone Propionate Nasal Spray, USP can relieve your allergy symptoms. For best results, it’s important to get a full dose. Here’s how, in five easy steps. 1. Shake Gently shake the bottle. Remove clear cap 2. Prime Do this when: Starting new bottle Haven’t used it in a week Just cleaned nozzle Otherwise go to Step 3. Aim away from face. Grasp spray bottle as shown. Pump until fine mist appears. Pumped six times and still no mist? Spray nozzle may be clogged. See KEEP IT CLEAN 3. Blow Blow nose gently to clear nostrils. 4. Aim Close one nostril and put tip of spray nozzle in other nostril. Put just the tip into your nose. Aim slightly away from center of nose. 5. Breathe and Spray While sniffing gently, press down on spray nozzle once or twice (according to dosing instructions). You’ll feel a light mist in your nose. Breathe out through your mouth. Repeat in other nostril . Wipe spray nozzle with clean tissue and replace cap Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520 Made in Italy image description image description image description image description image description image description image description image description image description image description image description image description image description image description image description image description image description image description"],"dosage_and_administration":["Directions read the Quick Start Guide for how to: prime the bottle use the spray clean the spray nozzle shake gently before each use use this product only once a day do not use more than directed ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER Week 1- use 2 sprays in each nostril once daily Week 2 through 6 months- use 1 or 2 sprays in each nostril once daily, as needed to treat your symptoms After 6 months of daily use – ask your doctor if you can keep using CHILDREN 4 TO 11 YEARS OF AGE the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief. Talk to your child’s doctor if your child needs to use the spray for longer than two months a year. an adult should supervise use use 1 spray in each nostril once daily CHILDREN UNDER 4 YEARS OF AGE do not use"],"spl_product_data_elements":["Fluticasone Propionate Fluticasone Propionate Nasal BENZALKONIUM CHLORIDE DEXTROSE MICROCRYSTALLINE CELLULOSE PHENYLETHYL ALCOHOL POLYSORBATE 80 WATER CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FLUTICASONE PROPIONATE FLUTICASONE"],"keep_out_of_reach_of_children":["Other information you may start to feel relief the first day and full effect after several days of regular, once-a-day use store between 4° and 30°C (39° and 86°F) keep this label and enclosed materials. They contain important additional information."],"spl_unclassified_section_table":["
FLUTICASONE PROPIONATE NASAL SPRAY, USP
QUESTIONS & ANSWERS
","
If you…Here’s what to do…
Are younger than 4Do not use Fluticasone PropionateNasal Spray, USP
Are pregnant or breast-feedingTalk to a health professional beforeusing Fluticasone Propionate Nasal Spray, USP
Have or had glaucoma or cataractsTalk to your doctor before using Fluticasone Propionate Nasal Spray, USP
Have an injury or surgery to yournosethat is not fully healed Do not use Fluticasone PropionateNasal Spray, USP
Have ever had an allergic reactionto Fluticasone Propionate Nasal Spray, USP or any of its ingredientsDo not use Fluticasone PropionateNasal Spray, USP
Are taking a medicine for HIV infection (such as ritonavir)Talk to your doctor or pharmacistbefore using Fluticasone Propionate Nasal Spray, USP
Are taking ketoconazole pills(medicine for fungal infection) Talk to your doctor or pharmacistbefore using Fluticasone Propionate Nasal Spray, USP
Are using a steroid medicine for asthma, allergies, skin rash, allergic reactions, inflammation or eye conditionsTalk to your doctor or pharmacistbefore using Fluticasone Propionate Nasal Spray, USP
","
If the label says…The bottle shouldlast age 12+…The bottle shouldlast age 4-11…
120 sprays4 weeks8 weeks
","
If you’re taking…Here’s what to do…
Medicines for HIV infection (such as ritonavir)Talk to your doctor or pharmacistbefore using Fluticasone PropionateNasal Spray, USP
Medicines with glucocorticoidsincluding some medicines for skinrash such as eczema, asthma,inflammation, allergic reactions oreye conditionsTalk to your doctor or pharmacistbefore using Fluticasone PropionateNasal Spray, USP
KetoconazolePills for fungal infectionTalk to your doctor or pharmacistbefore using Fluticasone PropionateNasal Spray, USP
","
AgesChildren 4-11 yearsof ageUsers 12 years of age and older
Dosage1 spray in each nostril once dailyUp to 2 sprays in each nostril once daily
Duration before checking with a doctorUp to 2 months of use a yearUp to 6 months of daily use
","
Side effectWhat could happenWhat to do
Allergic reaction tothe productSudden swelling of face or tongueA rashWheezing or feeling faintIf you feel any of these symptoms, stop using Fluticasone Propionate Nasal Spray, USP and see a doctor right away.
Nose injurySevere or frequent nosebleedsApply pressure to your nose. Stop using Fluticasone Propionate Nasal Spray, USP and see a doctor.
Constant whistling sound that does not go awayThis could be a sign of damage to your nose. Stop using Fluticasone Propionate Nasal Spray, USP and see a doctor right away.
Eye Conditionssuch as cataractsor glaucomaCloudy visionReduced visionHave a yearly eye exam to check for these conditions. Read the Drug Factson the back of the Fluticasone Propionate Nasal Spray, USP package for more details.
Growth effectsSlower growth rate in some children while using productTalk to your doctor if you are concerned or if a child age 4-11 needs to use Fluticasone Propionate Nasal Spray, USP for longer than two months a year.
Other side effectsHeadaches or sneezingBad taste or smellMinor nosebleedsDry or irritated nose or throatTalk to your doctor or pharmacist if you are concerned.
","
HOW TO START GETTING ALLERGY RELIEF RIGHT NOW
USE THE RIGHT DOSEFluticasone Propionate Nasal Spray, USP works best when you use it daily. Here’s how to get started.
Children age 4-11
An adult should supervise use Use one spray in each nostril Don’t use more than one spray in each nostril per day.If you miss a dose,just use your regular dose the next day. Don’t add an extra dose. Check with doctorif a child needs to use Fluticasone Propionate Nasal Spray, USP for longer than two months a year.
Users age 12 or older
In your first weekUse two sprays in each nostril every day.Don’t use more than two sprays in each nostril per day.After your first weekif your symptoms are under control, you may reduce to one spray in each nostril every day. If your symptoms get worse, go back to two sprays in each nostril. If you miss a dose,just use your regular dose the next day. Don’t add an extra dose. WARNING: Do not spray in your eyes. Only for use in your nose.
KEEP IT CLEANA clean spray nozzle helps ensure a full dose. Clean it weekly, or if it’s clogged. Don’t try to unblock nozzle with pin or sharp object — that can damage it.
Remove spray nozzle by grasping at base and pulling up.Aim away from your face and gently replace spray nozzle until you hear a soft click.Rinse under running tap, and dry at room temperature.If spray nozzle is clogged, soak in warm water. Then repeat steps 2and 3.
GET THE RELIEF YOU NEED.Fluticasone Propionate Nasal Spray, USP can relieve your allergy symptoms. For best results, it’s important to get a full dose. Here’s how, in five easy steps.
1. ShakeGently shake the bottle.Remove clear cap
2. Prime Do this when:Starting new bottleHaven’t used it in a weekJust cleaned nozzleOtherwise go to Step 3.Aim away from face.Grasp spray bottle as shown. Pump until fine mist appears.Pumped six times and still no mist? Spray nozzle may be clogged. See KEEP IT CLEAN
3. BlowBlow nose gently to clear nostrils. 4. AimClose one nostril and put tip of spray nozzle in other nostril. Put just the tip into your nose.Aim slightly away from center of nose.
5. Breathe and SprayWhile sniffing gently, press down on spray nozzle once or twice (according to dosing instructions). You’ll feel a light mist in your nose. Breathe out through your mouth.Repeat in other nostril. Wipe spray nozzle with clean tissue and replace cap
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Fluticasone propionate Nasal Spray 50 mcg per Spray - NDC 72888-248-01 - 120 Metered Spray Container Label Fluticasone propionate Nasal Spray 50 mcg per Spray - NDC 72888-248-01 - 120 Metered Spray Carton Label image description image description"]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"PGR","category":"gene"},{"label":"NR3C2","category":"gene"},{"label":"D07AC17","category":"atc"},{"label":"Topical","category":"route"},{"label":"Respiratory (Inhalation)","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Cream","category":"form"},{"label":"Lotion","category":"form"},{"label":"Ointment","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Allergic asthma","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Bronchospasm Prevention with COPD","category":"indication"},{"label":"COPD Associated with Chronic Bronchitis","category":"indication"},{"label":"Teva Pharm","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"21207 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"17325 reports"},{"date":"","signal":"ASTHMA","source":"FDA FAERS","actionTaken":"12424 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"10958 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"10633 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"10162 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"9707 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"8692 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"8227 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"7995 reports"}],"commonSideEffects":[{"effect":"Ear, nose, and throat disorders","drugRate":"29%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"27%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Palpitations","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Neurology disorders","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Muscle injuries","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Lower respiratory disorders","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Viral infections","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Musculoskeletal disorders","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Gastrointestinal signs and symptoms","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Nasal sinus disorders","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Sleep disorders","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Throat irritation","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Bacterial infections","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Skin flakiness and acquired ichthyosis","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Acute tuberculosis","Adrenal cortical hypofunction","Atrophoderma","Bacterial infectious disease","Bilateral cataracts","Candidiasis of mouth","Chronic myocardial ischemia","Conduction disorder of the heart","Congenital long QT syndrome","Diabetes mellitus","Disease caused by parasite","Disease of liver","Epistaxis","Exacerbation of asthma","Exposure to varicella","Glaucoma","Hypercortisolism","Hyperglycemia","Hypertensive disorder","Hypokalemia","Hypopituitarism","Inactive tuberculosis","Ketoacidosis","Measles","Mycosis"],"specialPopulations":{"Pregnancy":"There are insufficient data on the use of fluticasone propionate nasal spray in pregnant women to inform drug-associated risk. In animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight and/or skeletal variations, were observed in rats, mice, and rabbits with subcutaneously administered maternal toxic doses of fluticasone propionate times, equivalent to, and less than the maximum recommended human daily intranasal dose (MRHDID) on mcg/m2 basis, respectively. (See Animal Data.) However, fluticasone propionate administered via nose-only inhalation to rats decreased fetal body weight, but did not induce teratogenicity at maternal toxic dose equivalent to the MRHDID on mcg/m2 basis. (See Animal Data.) Experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. The estimated risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. DataHuman Data: Following inhaled administration, fluticasone propionate was detected in the neonatal cord blood after delivery. Animal Data: In embryofetal development studies with pregnant rats and mice dosed by the subcutaneous route throughout the","Geriatric use":"limited number of patients 65 years of age and older (n 129) or 75 years of age and older (n 11) have been treated with Fluticasone Propionate Nasal Spray, USP, in US and non-US clinical trials. While the number of patients is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger patients.","Paediatric use":"Six hundred fifty (650) patients aged to 11 years and 440 patients aged 12 to 17 years were studied in US clinical trials with Fluticasone Propionate Nasal Spray, USP. The safety and effectiveness of Fluticasone Propionate Nasal Spray, USP, in children below years of age have not been established.Controlled clinical studies have shown that intranasal corticosteroids may cause reduction in growth velocity in pediatric patients. This effect has been observed in the absence of labora"},"seriousAdverseEvents":[{"effect":"Pneumonia","drugRate":"2%","severity":"serious"},{"effect":"Elevation of hepatic enzymes","drugRate":"1%","severity":"serious"},{"effect":"Fractures","drugRate":"1%","severity":"serious"},{"effect":"Keratitis and conjunctivitis","drugRate":"1%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Teva Pharm","patents":[{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Sep 26, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11344685","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Feb 14, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10195375","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Aug 20, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11969544","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Dec 14, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10918816","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Jul 6, 2040","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11173259","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Aug 14, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10195375*PED","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Jun 14, 2036","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10918816*PED","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Jan 6, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11173259*PED","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Mar 26, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11344685*PED","drugSubstance":false},{"applNo":"N208798","source":"FDA Orange Book","status":"Active","expires":"Feb 20, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11969544*PED","drugSubstance":false},{"type":"Method of Use","number":"11554229","applicant":"PARATEK PHARMACEUTICALS INC","territory":"US","tradeName":"XHANCE","expiryDate":"2036-02-23"},{"type":"Method of Use","number":"12083270","applicant":"PARATEK PHARMACEUTICALS INC","territory":"US","tradeName":"XHANCE","expiryDate":"2031-04-04"},{"type":"Formulation","number":"7500444","applicant":"GLAXO GROUP LTD DBA GLAXOSMITHKLINE","territory":"US","tradeName":"FLOVENT HFA","expiryDate":"2026-02-26"},{"type":"Compound","number":"7500444*PED","applicant":"GLAXO GROUP LTD DBA GLAXOSMITHKLINE","territory":"US","tradeName":"FLOVENT HFA","expiryDate":"2026-08-26"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUTICASONE PROPIONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:26:46.858235+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:26:46.857013+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:27:09.129373+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:26:53.772306+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:26:46.878531+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:26:45.272632+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUTICASONE PROPIONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:26:54.552151+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:26:43.897715+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:26:43.897746+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:26:56.678611+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201396/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:26:55.425627+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA219060","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:26:43.897752+00:00"}},"allNames":"cutivate","offLabel":[],"synonyms":["fluticasone proprionate","fluticasone propionate","flixotide","fluticasone 17-propionate"],"timeline":[{"date":"1990-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from FOUGERA PHARMS to Teva Pharm"},{"date":"1990-12-14","type":"positive","source":"DrugCentral","milestone":"FDA approval (Fougera Pharms)"},{"date":"1994-10-19","type":"positive","source":"FDA Orange Book","milestone":"Flonase approved — 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1996-03-27","type":"positive","source":"FDA Orange Book","milestone":"Flovent approved — 0.044MG/INH"},{"date":"1997-11-07","type":"positive","source":"FDA Orange Book","milestone":"Flovent approved — 0.044MG/INH"},{"date":"2000-09-29","type":"positive","source":"FDA Orange Book","milestone":"Flovent Diskus 100 approved — 0.1MG/INH"},{"date":"2004-05-14","type":"positive","source":"FDA Orange Book","milestone":"Flovent Hfa approved — 0.044MG/INH"},{"date":"2005-03-31","type":"positive","source":"FDA Orange Book","milestone":"Cutivate approved — 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2014-07-23","type":"positive","source":"FDA Orange Book","milestone":"Flonase Allergy Relief approved — 0.05MG/SPRAY"},{"date":"2017-09-18","type":"positive","source":"FDA Orange Book","milestone":"Xhance approved — 0.093MG"},{"date":"2019-04-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 10 manufacturers approved"},{"date":"2020-06-29","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Kyorin Pharmaceutical Co., Ltd.)"},{"date":"2021-03-26","type":"positive","source":"DrugCentral","milestone":"EMA approval (Teva B.V.)"}],"aiSummary":"Cutivate, also known as fluticasone, is a small molecule medication used to treat various conditions, including Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, and Pain, among others. It is administered via inhalation and is prescribed per standard of care, with its pharmacokinetics, pharmacodynamics, and safety profile being studied in children.","approvals":[{"date":"1990-12-14","orphan":false,"company":"FOUGERA PHARMS","regulator":"FDA"},{"date":"2020-06-29","orphan":false,"company":"Kyorin Pharmaceutical Co., Ltd.","regulator":"PMDA"},{"date":"2021-03-26","orphan":false,"company":"TEVA B.V.","regulator":"EMA"}],"brandName":"Cutivate","ecosystem":[{"indication":"Allergic asthma","otherDrugs":[{"name":"formoterol","slug":"formoterol","company":"Novartis"},{"name":"mometasone furoate","slug":"mometasone-furoate","company":"Merck Sharp Dohme"},{"name":"montelukast","slug":"montelukast","company":"Merck"},{"name":"salmeterol","slug":"salmeterol","company":""}],"globalPrevalence":262000000},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Asthma management","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"}],"globalPrevalence":262000000},{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":204050000},{"indication":"Bronchospasm Prevention with COPD","otherDrugs":[{"name":"formoterol","slug":"formoterol","company":"Novartis"},{"name":"indacaterol","slug":"indacaterol","company":"Novartis"},{"name":"salmeterol","slug":"salmeterol","company":""},{"name":"tiotropium bromide","slug":"tiotropium-bromide","company":"Boehringer Ingelheim"}],"globalPrevalence":null},{"indication":"COPD Associated with Chronic Bronchitis","otherDrugs":[{"name":"formoterol","slug":"formoterol","company":"Novartis"},{"name":"roflumilast","slug":"roflumilast","company":"Astrazeneca Pharms"},{"name":"salmeterol","slug":"salmeterol","company":""},{"name":"theophylline","slug":"theophylline","company":"Gd Searle Llc"}],"globalPrevalence":null},{"indication":"Chronic Non-Allergic Rhinitis","otherDrugs":[{"name":"budesonide","slug":"budesonide","company":""},{"name":"desonide","slug":"desonide","company":"Perrigo New York"},{"name":"flunisolide","slug":"flunisolide","company":""},{"name":"fluticasone furoate","slug":"fluticasone-furoate","company":"Glaxosmithkline"}],"globalPrevalence":null},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":324000000}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"},{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"PLA2G4A","source":"DrugCentral","target":"Cytosolic phospholipase A2","protein":"Cytosolic phospholipase A2"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Cutivate (Fluticasone Propionate) is a synthetic corticosteroid that selectively binds to the glucocorticoid receptor, leading to the inhibition of transcription factors and subsequent reduction in the expression of pro-inflammatory genes."},"commercial":{"launchDate":"1990","revenueYear":2025,"_launchSource":"DrugCentral (FDA 1990-12-14, FOUGERA PHARMS)","annualRevenue":69,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1225","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUTICASONE%20PROPIONATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUTICASONE PROPIONATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:37:19.018826","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:27:09.129982+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"desoximetasone","drugSlug":"desoximetasone","fdaApproval":"1977-02-28","patentExpiry":"Sep 1, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluocinolone acetonide","drugSlug":"fluocinolone-acetonide","fdaApproval":"1963-02-15","patentExpiry":"Nov 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fludroxycortide","drugSlug":"fludroxycortide","fdaApproval":"1963-03-19","relationship":"same-class"},{"drugName":"fluocinonide","drugSlug":"fluocinonide","fdaApproval":"1971-06-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diflorasone diacetate","drugSlug":"diflorasone-diacetate","fdaApproval":"1977-09-14","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mometasone furoate","drugSlug":"mometasone-furoate","fdaApproval":"1987-04-30","patentExpiry":"Oct 3, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-class"},{"drugName":"hydrocortisone aceponate","drugSlug":"hydrocortisone-aceponate","fdaApproval":"","relationship":"same-class"},{"drugName":"fluticasone furoate","drugSlug":"fluticasone-furoate","fdaApproval":"2007-04-27","patentExpiry":"Oct 15, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednicarbate","drugSlug":"prednicarbate","fdaApproval":"1991-09-23","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"difluprednate","drugSlug":"difluprednate","fdaApproval":"2008-06-23","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ulobetasol propionate","drugSlug":"ulobetasol-propionate","fdaApproval":"1990-12-17","relationship":"same-class"}],"genericName":"fluticasone propionate","indications":{"approved":[{"name":"Allergic asthma","source":"DrugCentral","snomedId":389145006,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Bronchospasm Prevention with COPD","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"COPD Associated with Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Chronic Non-Allergic Rhinitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA"},{"name":"Non-allergic asthma","source":"DrugCentral","snomedId":266361008,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA"},{"name":"Pulmonary emphysema","source":"DrugCentral","snomedId":87433001,"regulator":"FDA"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"}],"offLabel":[{"name":"Severe chronic obstructive pulmonary disease","source":"DrugCentral","drugName":"FLUTICASONE PROPIONATE"}],"pipeline":[]},"currentOwner":"Teva Pharm","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"desoximetasone","brandName":"desoximetasone","genericName":"desoximetasone","approvalYear":"1977","relationship":"same-class"},{"drugId":"fluocinolone-acetonide","brandName":"fluocinolone acetonide","genericName":"fluocinolone acetonide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fludroxycortide","brandName":"fludroxycortide","genericName":"fludroxycortide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fluocinonide","brandName":"fluocinonide","genericName":"fluocinonide","approvalYear":"1971","relationship":"same-class"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-class"},{"drugId":"diflorasone-diacetate","brandName":"diflorasone diacetate","genericName":"diflorasone diacetate","approvalYear":"1977","relationship":"same-class"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-class"},{"drugId":"mometasone-furoate","brandName":"mometasone furoate","genericName":"mometasone furoate","approvalYear":"1987","relationship":"same-class"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":["Asthma"],"enrollment":2700,"completionDate":"2026-10-31"},{"nctId":"NCT06372496","phase":"PHASE4","title":"Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-04-16","conditions":["Asthma"],"enrollment":1366,"completionDate":"2027-03-31"},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":["Asthma"],"enrollment":1147,"completionDate":"2027-10-15"},{"nctId":"NCT06850805","phase":"PHASE3","title":"Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2025-07-28","conditions":["Chronic Rhinosinusitis Without Nasal Polyps"],"enrollment":84,"completionDate":"2028-10-31"},{"nctId":"NCT05608681","phase":"PHASE1,PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":["Eosinophilic Esophagitis"],"enrollment":117,"completionDate":"2026-12"},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":["Asthma"],"enrollment":724,"completionDate":"2026-05-31"},{"nctId":"NCT05309590","phase":"","title":"Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2014-05","conditions":["Eosinophilic Esophagitis"],"enrollment":50,"completionDate":"2027-11"},{"nctId":"NCT05275686","phase":"PHASE2","title":"Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-04-20","conditions":["Eustachian Tube Dysfunction"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT02476825","phase":"PHASE4","title":"A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2016-01-20","conditions":["Healthy"],"enrollment":30,"completionDate":"2026-10-31"},{"nctId":"NCT03742414","phase":"PHASE2","title":"Seal, Stopping Eczema and Allergy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kari Nadeau, MD, PhD","startDate":"2021-06-30","conditions":["Eczema, Infantile","Eczema","Atopic Dermatitis Eczema","Atopic Dermatitis"],"enrollment":398,"completionDate":"2028-06-30"},{"nctId":"NCT07415278","phase":"PHASE4","title":"INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pamukkale University","startDate":"2022-12-01","conditions":["Allergic Rhinitis"],"enrollment":61,"completionDate":"2026-10-30"},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":["Asthma"],"enrollment":20,"completionDate":"2030-12-31"},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":["Bronchiolitis Obliterans Syndrome","Bronchiolitis Obliterans","Lung Diseases","Chronic Graft Versus Host Disease"],"enrollment":45,"completionDate":"2027-12-31"},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":["Asthma Attack","Asthma Control","Asthma Exacerbations","Asthma"],"enrollment":40,"completionDate":"2027-04"},{"nctId":"NCT07223294","phase":"PHASE3","title":"Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma","status":"NOT_YET_RECRUITING","sponsor":"Sandoz","startDate":"2026-04","conditions":["Respiratory"],"enrollment":1430,"completionDate":"2026-10-31"},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":["Asthma"],"enrollment":304,"completionDate":"2029-12-24"},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":["Asthma"],"enrollment":250,"completionDate":"2026-12-31"},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":["COPD","Chronic Obstructive Pulmonary Disease (COPD)","Small Airway Disease","Triple Therapy","Lung Function"],"enrollment":22,"completionDate":"2026-01-28"},{"nctId":"NCT07380178","phase":"NA","title":"The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2025-04-01","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":40,"completionDate":"2025-07-05"},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":["COPD"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07324707","phase":"PHASE2","title":"Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma","status":"RECRUITING","sponsor":"Anhui Palo Alto Pharmaceuticals, Inc.","startDate":"2025-10-15","conditions":["Bronchial Asthma"],"enrollment":30,"completionDate":"2026-03"},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":["Moderate Asthma"],"enrollment":174,"completionDate":"2028-09"},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":["Community Acquired Pneumonia"],"enrollment":90,"completionDate":"2026-10-31"},{"nctId":"NCT07294326","phase":"PHASE4","title":"A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Union Hospital","startDate":"2026-01-01","conditions":["Allergic Rhinitis"],"enrollment":50,"completionDate":"2026-11-01"},{"nctId":"NCT05735431","phase":"PHASE3","title":"Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-06","conditions":["Moderate Asthma"],"enrollment":0,"completionDate":"2027-11"},{"nctId":"NCT05535972","phase":"PHASE4","title":"To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":463,"completionDate":"2023-09-25"},{"nctId":"NCT05292053","phase":"PHASE4","title":"Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2022-07-01","conditions":["Copd"],"enrollment":80,"completionDate":"2025-02-09"},{"nctId":"NCT05299086","phase":"PHASE3","title":"As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-04-04","conditions":["Perennial Allergic Rhinitis","Child, Only"],"enrollment":68,"completionDate":"2025-04-30"},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":["Covid19"],"enrollment":10956,"completionDate":"2024-04-29"},{"nctId":"NCT05535738","phase":"PHASE2,PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":["Skin Inflammation","Allergic Contact Dermatitis"],"enrollment":45,"completionDate":"2027-12-31"},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":["Asthma","Asthma Attack","Asthma Exacerbations"],"enrollment":3200,"completionDate":"2029-11-15"},{"nctId":"NCT05757102","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-04-25","conditions":["Asthma"],"enrollment":292,"completionDate":"2027-01-15"},{"nctId":"NCT05095116","phase":"","title":"Expanded Access Protocol for Patients With Eosinophilic Esophagitis","status":"NO_LONGER_AVAILABLE","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"","conditions":["Eosinophilic Esophagitis"],"enrollment":0,"completionDate":""},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":60,"completionDate":"2027-10"},{"nctId":"NCT06040268","phase":"PHASE1,PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":["Altitude Edema"],"enrollment":60,"completionDate":"2026-12-15"},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":["Stem Cell Transplant Complications","Respiratory Disease","Bronchiolitis Obliterans"],"enrollment":35,"completionDate":"2023-09-27"},{"nctId":"NCT06858137","phase":"NA","title":"Thread Embedding Acupuncture For Rhinitis Allergy","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2024-12-15","conditions":["Rhinitis Allergic"],"enrollment":64,"completionDate":"2025-07-31"},{"nctId":"NCT04651777","phase":"PHASE3","title":"Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-08-08","conditions":["Asthma"],"enrollment":31,"completionDate":"2025-12"},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":["Asthma"],"enrollment":30,"completionDate":"2024-10-07"},{"nctId":"NCT05634746","phase":"PHASE3","title":"24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2022-12-29","conditions":["Eosinophilic Esophagitis"],"enrollment":218,"completionDate":"2024-08-12"},{"nctId":"NCT05457855","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-02-01","conditions":["Asthma"],"enrollment":51533,"completionDate":"2023-12-31"},{"nctId":"NCT04937387","phase":"PHASE3","title":"Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-07-29","conditions":["Asthma"],"enrollment":359,"completionDate":"2024-08-05"},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":["Atopic Rhinitis","Atopic Asthma"],"enrollment":200,"completionDate":"2026-05"},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":["Persistent Asthma","Asthma in Children","Asthma Exacerbation"],"enrollment":525,"completionDate":"2030-12-31"},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":["COPD (Chronic Obstructive Pulmonary Disease)","Acupuncture"],"enrollment":60,"completionDate":"2026-01-15"},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":["Asthma"],"enrollment":906,"completionDate":"2022-03-21"},{"nctId":"NCT05545072","phase":"PHASE3","title":"Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-10-26","conditions":["Allergic Fungal Rhinosinusitis"],"enrollment":5,"completionDate":"2024-07-10"},{"nctId":"NCT06474039","phase":"PHASE3","title":"The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-10-01","conditions":["COPD"],"enrollment":50,"completionDate":"2026-12"},{"nctId":"NCT05706636","phase":"NA","title":"T Central Memory Cells in Early Localized Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-02-01","conditions":["Vitiligo"],"enrollment":22,"completionDate":"2025-04-15"},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":["Asthma","Bronchial Diseases","Respiratory Tract Infections","Lung Diseases, Obstructive","Lung Diseases","Respiratory Hypersensitivity","Immune System Diseases"],"enrollment":103,"completionDate":"2024-12-31"},{"nctId":"NCT06066606","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Vilanterol","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2023-10-03","conditions":["Exercise Performance"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT06077019","phase":"NA","title":"Role of Lung Function for Exercise Capacity in Well-trained Individuals","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2023-10-03","conditions":["Exercise Performance"],"enrollment":60,"completionDate":"2026-12-01"},{"nctId":"NCT01202097","phase":"PHASE3","title":"A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":["Asthma"],"enrollment":334,"completionDate":"2012-05"},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":["COPD"],"enrollment":48,"completionDate":"2028-12-31"},{"nctId":"NCT04923347","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-06-06","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":229,"completionDate":"2024-03-14"},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":["Asthma"],"enrollment":20,"completionDate":"2024-10-25"},{"nctId":"NCT06705387","phase":"PHASE2","title":"Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-12-23","conditions":["Eosinophilic Esophagitis"],"enrollment":72,"completionDate":"2027-03"},{"nctId":"NCT06858423","phase":"PHASE4","title":"Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-08-15","conditions":["Nasal Allergy"],"enrollment":360,"completionDate":"2024-05-31"},{"nctId":"NCT02989935","phase":"PHASE4","title":"RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2016-04","conditions":["Copd"],"enrollment":30,"completionDate":"2026-07-01"},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":1252,"completionDate":"2028-08"},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":["Asthma"],"enrollment":9,"completionDate":"2011-12-14"},{"nctId":"NCT06806826","phase":"PHASE4","title":"The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2019-01-01","conditions":["Allergic Rhinitis"],"enrollment":50,"completionDate":"2020-03-01"},{"nctId":"NCT02630121","phase":"PHASE4","title":"Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea","status":"RECRUITING","sponsor":"University of South Florida","startDate":"2023-04-01","conditions":["Sleep Apnea","Chronic Nasal Congestion"],"enrollment":52,"completionDate":"2026-04"},{"nctId":"NCT01624129","phase":"","title":"New Serological Markers for Eosinophilic Esophagitis","status":"UNKNOWN","sponsor":"Technical University of Munich","startDate":"2011-01","conditions":["Eosinophilic Esophagitis"],"enrollment":20,"completionDate":""},{"nctId":"NCT03040596","phase":"PHASE1","title":"The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children","status":"TERMINATED","sponsor":"Joseph Dohar, MD","startDate":"2017-03-01","conditions":["Vocal Fold Nodules"],"enrollment":2,"completionDate":"2019-01-23"},{"nctId":"NCT03072849","phase":"","title":"Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2015-04","conditions":["Bronchiolitis Obliterans Syndrome"],"enrollment":23,"completionDate":"2020-09-01"},{"nctId":"NCT03002389","phase":"PHASE2","title":"Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2017-11-05","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":95,"completionDate":"2028-01-31"},{"nctId":"NCT05444543","phase":"PHASE4","title":"Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2021-11-17","conditions":["Eosinophilic Esophagitis"],"enrollment":23,"completionDate":"2023-10-13"},{"nctId":"NCT06323304","phase":"NA","title":"Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2024-03-13","conditions":["Itching","Runny Nose","Sneezing","Nasal Congestion"],"enrollment":90,"completionDate":"2024-08-30"},{"nctId":"NCT06650917","phase":"PHASE1","title":"Acupoint Massage Combined With Ear Point Pressing Beans","status":"COMPLETED","sponsor":"Hai'an Hospital of TCM001","startDate":"2016-01-01","conditions":["Asthma"],"enrollment":120,"completionDate":"2022-12-01"},{"nctId":"NCT02402465","phase":"PHASE4","title":"Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-02","conditions":["Allergic Rhinitis"],"enrollment":22,"completionDate":"2020-02"},{"nctId":"NCT05192499","phase":"NA","title":"Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-02-04","conditions":["Asthma in Children","Dysbiosis"],"enrollment":30,"completionDate":"2028-02-04"},{"nctId":"NCT03199976","phase":"PHASE4","title":"Efficacy of Intermittent Tiotropium in Early Childhood Wheezing","status":"TERMINATED","sponsor":"Helsinki University Central Hospital","startDate":"2016-04-20","conditions":["Wheezy Bronchitis","Asthmatic Bronchitis","Wheezing","Obstruction Airway"],"enrollment":80,"completionDate":"2020-11-18"},{"nctId":"NCT00545324","phase":"PHASE4","title":"First Step With Singulair® Therapy (0476-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":["Asthma"],"enrollment":399,"completionDate":"2003-12"},{"nctId":"NCT00817050","phase":"PHASE4","title":"Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":["Allergic Rhinitis"],"enrollment":100,"completionDate":"2005-01-01"},{"nctId":"NCT00489346","phase":"PHASE3","title":"A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10","conditions":["Asthma, Bronchial"],"enrollment":994,"completionDate":"2002-06"},{"nctId":"NCT00763529","phase":"PHASE4","title":"Elocon vs Fluticasone in Localized Psoriasis (P03197)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01-01","conditions":["Psoriasis"],"enrollment":245,"completionDate":"2005-01-01"},{"nctId":"NCT00783458","phase":"PHASE4","title":"Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":["Allergic Rhinitis"],"enrollment":100,"completionDate":"2005-01-01"},{"nctId":"NCT04527016","phase":"PHASE4","title":"Airway Microbiota Based Treatment of Asthma in Preschool Children","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-18","conditions":["Asthma in Children"],"enrollment":120,"completionDate":"2024-06-20"},{"nctId":"NCT06482294","phase":"PHASE2","title":"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2024-06-18","conditions":["Asthma"],"enrollment":80,"completionDate":"2025-07-01"},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":["Asthma"],"enrollment":566,"completionDate":"2009-10"},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":["Asthma"],"enrollment":722,"completionDate":"2008-11"},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":["Asthma"],"enrollment":404,"completionDate":"2007-11"},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":["Exercise Induced Asthma"],"enrollment":154,"completionDate":"2008-11"},{"nctId":"NCT00284856","phase":"PHASE3","title":"Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":["Asthma"],"enrollment":1640,"completionDate":"2010-04"},{"nctId":"NCT01966692","phase":"PHASE1","title":"Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-11","conditions":["Asthma"],"enrollment":24,"completionDate":"2018-01-20"},{"nctId":"NCT05080322","phase":"PHASE4","title":"Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis","status":"RECRUITING","sponsor":"Zheng Liu ENT","startDate":"2021-09-09","conditions":["Allergic Rhinitis"],"enrollment":150,"completionDate":"2025-01-01"},{"nctId":"NCT03858348","phase":"","title":"A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2019-05-01","conditions":["COPD","COPD Exacerbation"],"enrollment":1000,"completionDate":"2019-12-31"},{"nctId":"NCT00235053","phase":"PHASE4","title":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","status":"COMPLETED","sponsor":"Allergy & Asthma Medical Group & Research Center","startDate":"2005-08","conditions":["Asthma","Candidiasis, Oral","Voice Disorders"],"enrollment":13,"completionDate":"2005-11"},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":["Asthma"],"enrollment":477,"completionDate":"2021-06-04"},{"nctId":"NCT06180083","phase":"PHASE1","title":"Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-03-24","conditions":["Seasonal Allergic Rhinitis","Perennial Allergic Rhinitis"],"enrollment":56,"completionDate":"2023-07-05"},{"nctId":"NCT05158972","phase":"","title":"Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-10-27","conditions":["Allergic Rhinitis"],"enrollment":924,"completionDate":"2023-10-24"},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":11316,"completionDate":"2022-02-03"},{"nctId":"NCT01484210","phase":"PHASE3","title":"Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-03","conditions":["Asthma"],"enrollment":28,"completionDate":"2008-10"},{"nctId":"NCT04601324","phase":"PHASE4","title":"Allergic Rhinitis Combination Pharmacotherapy Efficacy Study","status":"WITHDRAWN","sponsor":"St. Paul's Sinus Centre","startDate":"2020-12-15","conditions":["Allergic Rhinitis"],"enrollment":0,"completionDate":"2021-07-01"},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":["Asthma"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":["Asthma"],"enrollment":50,"completionDate":"2027-06"},{"nctId":"NCT05169424","phase":"","title":"A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-17","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":9117,"completionDate":"2021-12-27"},{"nctId":"NCT06051786","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Synmosa Biopharma Corp.","startDate":"2020-08-20","conditions":["Allergic Rhinitis"],"enrollment":136,"completionDate":"2021-07-20"},{"nctId":"NCT05083312","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2021-09-30","conditions":["Eosinophilic Esophagitis"],"enrollment":6,"completionDate":"2022-09-05"}],"_emaApprovals":[{"date":"2021-03-26","status":"Authorised","company":"TEVA B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Nasal","formulation":"Aerosol, Cream, Lotion, Ointment","formulations":[{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"ADVAIR HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"FLOVENTHFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Fluticasone Propionate and Salmeterol HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Fluticasone PropionateHFA"},{"form":"CREAM","route":"TOPICAL","productName":"FLUTICASONE PROPIONATE"},{"form":"CREAM","route":"TOPICAL","productName":"Fluticasone Propionate"},{"form":"CREAM","route":"TOPICAL","productName":"Cutivate"},{"form":"CREAM","route":"TOPICAL","productName":"FLUTICASONE PROPIONATE 0.05% / NIACINAMIDE 4%"},{"form":"LOTION","route":"TOPICAL","productName":"Fluticasone Propionate"},{"form":"LOTION","route":"TOPICAL","productName":"fluticasone propionate"},{"form":"LOTION","route":"TOPICAL","productName":"Cutivate"},{"form":"LOTION","route":"TOPICAL","productName":"FLUTICASONE PROPIONATE"},{"form":"OINTMENT","route":"TOPICAL","productName":"Fluticasone Propionate"},{"form":"POWDER","route":"RESPIRATORY (INHALATION)","productName":"Wixela Inhub"},{"form":"POWDER","route":"RESPIRATORY (INHALATION)","productName":"fluticasone propionate and salmeterol"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148122","MMSL":"4756","NDDF":"003593","UNII":"O2GMZ0LF5W","VUID":"4020180","CHEBI":"CHEBI:31441","VANDF":"4020180","INN_ID":"5636","RXNORM":"41126","UMLSCUI":"C0117996","chemblId":"CHEMBL1201396","ChEMBL_ID":"CHEMBL1473","KEGG_DRUG":"D01708","DRUGBANK_ID":"DB00588","PUBCHEM_CID":"444036","SNOMEDCT_US":"108632003","IUPHAR_LIGAND_ID":"7080","SECONDARY_CAS_RN":"90566-53-3","MESH_DESCRIPTOR_UI":"D000068298"},"formularyStatus":[],"originalProduct":{"form":"CREAM","route":"TOPICAL","company":"PharmaDerm a division of Fougera Pharmaceuticals Inc.","brandName":"Cutivate","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1990-","companyName":"Fougera Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Teva Pharm","relationship":"Current Owner"},{"period":"2020","companyName":"Kyorin Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"},{"period":"2021","companyName":"Teva B.V.","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"6.0 hours","clearance":"17.0 mL/min/kg","bioavailability":"1%","fractionUnbound":"0.1%","volumeOfDistribution":"3.6 L/kg"},"publicationCount":2748,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-03-31 14:09:31.916777+00","atcClassification":{"source":"DrugCentral","atcCode":"D07AC17","allCodes":["D07AC17","R01AD08","R01AD58","R03AK06","R03AK11","R03BA05"]},"biosimilarFilings":[],"originalDeveloper":"Fougera Pharms","recentPublications":[],"combinationProducts":[{"brandName":"ADVAIR DISKUS","ingredients":"fluticasone propionate + salmeterol"},{"brandName":"ADVAIR HFA","ingredients":"fluticasone propionate + salmeterol"},{"brandName":"ADVAIRDISKUS","ingredients":"fluticasone propionate + salmeterol"},{"brandName":"AirDuo Digihaler","ingredients":"fluticasone propionate + salmeterol"},{"brandName":"AirDuo RespiClick","ingredients":"fluticasone propionate + salmeterol"},{"brandName":"DYMISTA","ingredients":"azelastine + fluticasone propionate"}],"companionDiagnostics":[],"genericManufacturers":15,"_genericFilersChecked":true,"genericManufacturerList":["Apotex","Aurobindo Pharma Ltd","Bright","Chartwell Rx","Cosette","Encube","Fougera Pharms","Glenmark Pharms Ltd","Glenmark Speclt","Hikma","Nesher Pharms","Padagis Israel","Rubicon","Rubicon Research","Taro Pharm Inds"],"status":"approved","companyName":"Teva Pharm","companyId":"teva","modality":"Small molecule","firstApprovalDate":"1990","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":"CUTIVATE","application_number":"NDA019957"},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1990-12-14T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-12-18T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":"CUTIVATE","application_number":"NDA019958"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-05-14T00:00:00.000Z","mah":"ENCUBE","brand_name_local":null,"application_number":"ANDA076633"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-03-31T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":"CUTIVATE","application_number":"NDA021152"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-03-03T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA077168"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-07T00:00:00.000Z","mah":"GLAXO GRP LTD","brand_name_local":null,"application_number":"NDA021254"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-06-29T00:00:00.000Z","mah":"Kyorin Pharmaceutical Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2021-03-26T00:00:00.000Z","mah":"TEVA B.V.","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-15T00:00:00.000Z","mah":"RUBICON","brand_name_local":null,"application_number":"ANDA219060"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-03T00:00:00.000Z","mah":"GLENMARK SPECLT","brand_name_local":null,"application_number":"ANDA219602"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:27:09.129982+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}